Morgan Stanley’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-225
| Closed | -$4K | – | 7678 |
|
|
2020
Q4 | $4K | Sell |
225
-76,303
| -100% | -$1.07M | ﹤0.01% | 6831 |
|
|
2020
Q3 | $896K | Sell |
76,528
-105,116
| -58% | -$1.39M | ﹤0.01% | 4284 |
|
|
2020
Q2 | $2.36M | Buy |
181,644
+36,571
| +25% | +$439K | ﹤0.01% | 3444 |
|
|
2020
Q1 | $1.34M | Buy |
145,073
+40,025
| +38% | +$559K | ﹤0.01% | 3717 |
|
|
2019
Q4 | $1.74M | Sell |
105,048
-120,949
| -54% | -$1.96M | ﹤0.01% | 4139 |
|
|
2019
Q3 | $3.76M | Sell |
225,997
-282,111
| -56% | -$3.9M | ﹤0.01% | 3183 |
|
|
2019
Q2 | $6.99M | Buy |
508,108
+176,377
| +53% | +$2.7M | ﹤0.01% | 2559 |
|
|
2019
Q1 | $5.71M | Buy |
331,731
+233,797
| +239% | +$3.7M | ﹤0.01% | 2577 |
|
|
2018
Q4 | $1.25M | Buy |
97,934
+53,498
| +120% | +$811K | ﹤0.01% | 4117 |
|
|
2018
Q3 | $721K | Sell |
44,436
-45,327
| -50% | -$648K | ﹤0.01% | 4769 |
|
|
2018
Q2 | $1.16M | Buy |
89,763
+35,086
| +64% | +$474K | ﹤0.01% | 4523 |
|
|
2018
Q1 | $681K | Sell |
54,677
-5,696
| -9% | -$69.3K | ﹤0.01% | 4813 |
|
|
2017
Q4 | $844K | Buy |
60,373
+28,495
| +89% | +$417K | ﹤0.01% | 4662 |
|
|
2017
Q3 | $536K | Buy |
31,878
+7,696
| +32% | +$125K | ﹤0.01% | 4841 |
|
|
2017
Q2 | $407K | Sell |
24,182
-4,994
| -17% | -$74.6K | ﹤0.01% | 4931 |
|
|
2017
Q1 | $452K | Sell |
29,176
-35,432
| -55% | -$506K | ﹤0.01% | 4901 |
|
|
2016
Q4 | $966K | Buy |
64,608
+60,551
| +1,493% | +$850K | ﹤0.01% | 4486 |
|
|
2016
Q3 | $51K | Buy |
+4,057
| New | +$40.7K | ﹤0.01% | 5587 |
|
|
2016
Q1 | – | Sell |
-27,862
| Closed | -$321K | – | 6801 |
|
|
2015
Q4 | $321K | Buy |
27,862
+23,650
| +561% | +$293K | ﹤0.01% | 4826 |
|
|
2015
Q3 | $57K | Buy |
4,212
+3,900
| +1,250% | +$52.9K | ﹤0.01% | 5680 |
|
|
2015
Q2 | $4K | Buy |
+312
| New | +$4.22K | ﹤0.01% | 6452 |
|
|
2015
Q1 | – | Sell |
-8
| Closed | – | – | 6721 |
|
|
2014
Q4 | $0 | Sell |
8
-524
| -98% | -$7.16K | ﹤0.01% | 6732 |
|
|
2014
Q3 | $8K | Buy |
532
+498
| +1,465% | +$7.63K | ﹤0.01% | 6250 |
|
|
2014
Q2 | $1K | Sell |
34
-2
| -6% | -$36 | ﹤0.01% | 6455 |
|
|
2014
Q1 | $1K | Buy |
36
+27
| +300% | +$584 | ﹤0.01% | 6410 |
|
|
2013
Q4 | $0 | Buy |
+9
| New | +$159 | ﹤0.01% | 6377 |
|
Morgan Stanley's OXFD Position: Q1 2021 in Review
Morgan Stanley sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q1 2021, closing a stake of 225 shares — an estimated $4K sold.
Morgan Stanley first reported a position in OXFD in Q4 2013 and held it in 26 quarters. The position peaked at $6.99M in Q2 2019. 0 funds tracked by Wall St. Rank hold OXFD as of Q1 2021.
- Morgan Stanley reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q1 2021 after selling out during the quarter.
- Morgan Stanley sold 225 Oxford Immunotec Global PLC Ordinary Shares shares in Q1 2021, an estimated $4K.
- Morgan Stanley first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q4 2013 and held it in 26 quarters.
- Morgan Stanley's Oxford Immunotec Global PLC Ordinary Shares position peaked at $6.99M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q1 2021.
Based on Morgan Stanley's 13F filing for Q1 2021, filed 17 May 2021.